T.Man Pharmaceutical Public Company Limited, or TMAN, has announced its business plan for the second half of 2026, using an aggressive marketing strategy and building a new S-curve in longevity. The company will launch 7 to 10 core brand products over the next six months to push this year's revenue growth to 10 to 15 percent from the previous year. Chief Executive Officer Praphon Thanachotiphan said the company will accelerate expansion in the pharmacy market, upgrade its OEM and ODM business, expand overseas markets such as Korea and China, penetrate the hospital market with new medicines for chronic non-communicable diseases, strengthen e-commerce channels, and manage costs to cope with geopolitical impacts. First-half performance showed total revenue of 1.2281 billion baht, up 8.2 percent from the previous year, but net profit of 212.2 million baht fell 7.2 percent from the previous year due to higher marketing expenses and higher corporate income tax from the expiry of one investment promotion certificate. In the second quarter of 2026, revenue was 594.4 million baht, up 11.0 percent from the previous year, and net profit was 97.6 million baht, down 8.6 percent from the previous year. The distribution business for third-party brands grew 776 percent from the previous year, and the contract manufacturing business grew 631 percent from the previous year. Meanwhile, the gross profit margin of the core business was 49.8 percent, down slightly from 51.4 percent in the previous year. The board of directors approved an interim dividend for the first half of 2026 at 0.24 baht per share, totaling 96,000,864 baht, with the XD date set for 26 August 2026 and dividend payment on 8 September 2026.
T Man Pharmaceutical PCLCompany plans aggressive marketing and new product launches to drive revenue growth, indicating strong demand initiatives.
